Qvanteq raises €4.2M Series B round
12 February 2013· Zurich, Switzerland· health, biotech, materials, b2b, software_hardware
to obtain clinical proof of concept in a 'First-in-Man' study as well as CE market approval for Qvanteq's own novel coronary stent device
Investors
Leadprivate investors
About Qvanteq
Stage
Series B
Headquarters
Zurich, Switzerland
Founded
2009
Team Size
1–5
Sectors
healthbiotechmaterialsb2bsoftware_hardware